Translocation T(14;16) in Multiple Myeloma: Gangster or Just Part of the Gang?

Overview

Journal Blood Cancer J

Date 2024 Jan 15

PMID 38225228

Authors

Hira Mian

Martin Kaiser

Rafael Fonseca

Affiliations

Soon will be listed here.

Citing Articles

A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs.

Li Y, Liu J, Deng J, Jian Y, Zhang Z, Zhou H Front Med (Lausanne). 2024; 11:1473034.

PMID: 39502644 PMC: 11536264. DOI: 10.3389/fmed.2024.1473034.

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management.

More S, Corvatta L, Manieri V, Morsia E, Offidani M Cancers (Basel). 2024; 16(12).

PMID: 38927968 PMC: 11202048. DOI: 10.3390/cancers16122263.

References

Benboubker L, Dimopoulos M, Dispenzieri A, Catalano J, Belch A, Cavo M . Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371(10):906-17. DOI: 10.1056/NEJMoa1402551. View

Schavgoulidze A, Perrot A, Cazaubiel T, Leleu X, Montes L, Jacquet C . Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood Cancer J. 2023; 13(1):160. PMC: 10600097. DOI: 10.1038/s41408-023-00933-4. View

DAgostino M, Cairns D, Lahuerta J, Wester R, Bertsch U, Waage A . Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022; 40(29):3406-3418. DOI: 10.1200/JCO.21.02614. View

Walker B, Wardell C, Murison A, Boyle E, Begum D, Dahir N . APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015; 6:6997. PMC: 4568299. DOI: 10.1038/ncomms7997. View

Panopoulou A, Easdale S, Ethell M, Nicholson E, Potter M, Giotas A . Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients. Hemasphere. 2023; 7(2):e831. PMC: 9894354. DOI: 10.1097/HS9.0000000000000831. View

Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A . Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2022; 24(1):64-76. DOI: 10.1016/S1470-2045(22)00693-3. View

Costa L, Chhabra S, Medvedova E, Dholaria B, Schmidt T, Godby K . Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021; 40(25):2901-2912. DOI: 10.1200/JCO.21.01935. View

McCarthy P, Holstein S, Petrucci M, Richardson P, Hulin C, Tosi P . Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017; 35(29):3279-3289. PMC: 5652871. DOI: 10.1200/JCO.2017.72.6679. View

Hurt E, Wiestner A, Rosenwald A, Shaffer A, Campo E, Grogan T . Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004; 5(2):191-9. DOI: 10.1016/s1535-6108(04)00019-4. View

10.

Croft J, Ellis S, Sherborne A, Sharp K, Price A, Jenner M . Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia. 2020; 35(7):2043-2053. PMC: 8257500. DOI: 10.1038/s41375-020-01096-y. View

11.

Kumar S, Rajkumar S . The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018; 15(7):409-421. DOI: 10.1038/s41571-018-0018-y. View

12.

Fonseca R, Blood E, Rue M, Harrington D, Oken M, Kyle R . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003; 101(11):4569-75. DOI: 10.1182/blood-2002-10-3017. View

13.

Kumar S, Harrison S, Cavo M, Rubia J, Popat R, Gasparetto C . Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1630-1642. DOI: 10.1016/S1470-2045(20)30525-8. View